Seite 78 von 155
Neuester Beitrag: 12.07.20 06:54
|Eröffnet am:||17.09.13 23:22||von: Balu4u||Anzahl Beiträge:||4.853|
|Neuester Beitrag:||12.07.20 06:54||von: up08||Leser gesamt:||484.749|
|Seite: < 1 | ... | 75 | 76 | 77 | | 79 | 80 | 81 | ... 155 >|
Additionally, for those in whom progression occurs several months or years after the last dose of PD-L1 blockade, immunotherapy rechallenge may be attempted, as some responses have been reported.
CONCLUSIONS Acquired resistance to PD-1 axis inhibitors is often limited to one or two sites when local therapy and continuation of PD-1 axis inhibitor therapy can result in prolonged benefit. LN metastases appear to be particularly susceptible sites to AR. When progression of disease following response occurs after holiday from PD-1 axis inhibitor, re-challenge can again lead to tumor regression.
A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung CancerINCLUSION CRITERIA:
Arm 5: Received at least one prior line of therapy for incurable or metastatic NSCLC. Up to one prior line of checkpoint inhibitor therapy is permitted (must have received at least 4 months of treatment)
Refractory to prior immunotherapy (clinical or radiographic progression after 12 weeks or less of immunotherapy).